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The agglutinating  and mitogenic  effects  of phyto-
hemoagglutinin  (PHA)  on  blood  cells  are  well
documented.  With  lymphocytes,  the  process  is
termed  "blastogenesis"  and  involves  morpho-
logical  and biochemical  alterations  in which  non-
proliferating  cells  become  transformed  into
lymphoblasts  capable  of  mitosis.  The  earliest
known  biochemical  changes  evident  within  an
hour are the stimulation of ribonucleic acid (RNA)
(1,  2)  and  protein synthesis  (3,  4),  the acetylation
of histones  (4,  5),  and  phosphorylation  of nuclear
proteins  (6).  This may  be regarded  as an  increase
of nuclear activity  (4).  Later,  by 26  hr,  some en-
zymes of the glycolytic pathway and phosphoryla-
tion are also stimulated (7)  as well as the hydrolases
associated  with  lysosomes  (8).  The  synthesis  of
DNA and mitosis take place much later, occurring
between 48 and 72 hr after exposure to PHA.
Nowell  (9)  and  Hastings  et  al.  (10)  have  sug-
gested that  blastogenesis  in  vitro might be related
to activity  of the PHA at the cell membrane  either
by affecting  permeability  directly  (9) or indirectly
because  of  clumping,  thereby  "providing  an  en-
vironment  similar to  that  in  a plasma  clot"  (10).
Although  PHA  possesses  both  the  property  to
agglutinate  and  the  property  to  transform  cells
(11),  Barjeson  (12)  could  dissociate  these  two  ac-
tivities  by adsorbing  N-acetyl-D-galacturonic  acid
onto  lymphocytes,  thereby  preventing  agglutina-
tion without blocking the blastogenic  capability of
PHA.
It  has  been  reported  that  N-acetyl-D-galactos-
amine, one of the amino sugars contained in mam-
malian  cell  surfaces,  can interfere  with  agglutina-
tion by PHA (13).  On the other hand, amantadine
(1-amantanamine  HCl,  Symmetrel,  E.  I.  du Pont
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pound known  to have  membrane-binding  proper-
ties,  can  inhibit  the  mitogenic  response  without
interfering  with the ability  of PHA  to agglutinate
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lymphocytes.  It  was then  suggested that PHA and
amantadine alter the cell membrane  by acting at a
common  site  on  it  (14).  In  order  to  learn  more
about  the  early  biochemical  changes  induced  by
PHA  and  their possible  relationship  with the  cell
membrane  involvement,  the  effect  of these  com-
pounds  on  the RNA synthesis  following  induction
by  PHA  was studied.  Permeability  changes  were
also  investigated  by  the  measurement  of  the
amount  of  soluble  radioactive  precursors  under
different  conditions.
MATERIAL  AND  METHODS
Detailed  description  of  the  nutrient  media,  prep-
aration  of lymphocytes  cultures,  and  experimental
methods  have  been  published  (4,  5).  Cell  culture
density  (5  X  106  cells  per ml)  and Phytohemoagglu-
tinin  "P"  (Difco  Mfr.  Co.,  Detroit)  concentration
(0.5 mg per  ml)  were  maintained  constant  in all the
experiments.
N-acetyl-D-galactosamine  and  N-acetyl-D-gluco-
samine  were obtained  from Mann  Research  Labora-
Liry,  IN.  I . tmLatame  rl  I  was.t  Wd  gL  hIll'  Drt. 
L.  Daries  of  E.  I.  du  Pont de  Nemours  Co.,  Inc.
Uridine-2-1
4C  (sp.  act.  50  mc/mmole  and  32  mc/
mmole)  and  D-alanine-UL-1
4 C  (sp.  act.  112  mc/
mmole)  were  added  to the tissue  culture medium  in
concentrations  of  1  c  per  ml.  Na  acetate-2-1
4C
(sp.  act.  22.5  mc/mmole)  was  added  in concentra-
tions of 5 yc per ml.
After  incubation  with  the  radioactive  precursors,
the cells  were  washed  twice  with cold  tissue culture
medium,  precipitated  with  2%  perchloric  acid
(PCA)  in the cold,  and washed  twice with  2%  PCA.
The  PCA  extracts  were  pooled  so  as  to  measure
soluble  radioactivity.  Lipids  were extracted  from the
0  PCA  precipitates  with  alcohol  and  alcohol:chloro-
AMANTADINE
form:ether  (3:1:1)  for  5  mrnin  at  60'C.  RNA  and
protein  were  determined  as  in  reference  4.  Radio-
FIGURE  1  A,  Effect  of  varying  concentrations  of
N-acetyl-D-galactosamine  on  the  uridine-2-'
4 C  uptake
into  RNA  of  equine lymphocytes.  0-------- ,  control
cells;  ---- A,  PHA-treated  cells.  B, Effect of vary-
ing concentrations  of amantadine  hydrochloride  on the
uridine-2-
54C  uptake into RNA of equine lymphocytes.
0-------  ,  control  cells;  A-  A,  PHA-treated
cells. C, Lack of effect on RNA synthesis  of N-acetyl-D-
galactosamine  applied  to  lymphocytes  previously
treated  with  PHA.  A - ,  PHA-treated  cells;
A--A,  PHA-treated  cells +  N-acetyl-D-galactosa-
mine  (6  mg/ml);  --  ,  PHA-treated  cells  +
amantadine  hydrochloride  (10  g/ml);  0-------0,
control  cells;  ·--  ,  control  cells  +  N-acetyl-D-
galactosamine  (6 mg/ml);  0  0,  control  cells  +
amantadine  hydrochloride  (10  tpg/ml).
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572  B  R  I  E  F  N  O  T  E  Sactivity  was  counted  in  a  Beckman  Scintillation
Counter model LS-200B.  Efficiency for 1
4C was 85%.
RESULTS  AND  DISCUSSION
As was anticipated  from our previous  work  (4,  5),
there was an increased  incorporation of radioactive
precursors  into  RNA  shortly  after  the  addition  of
PHA to lymphocyte cultures.  Two series of experi-
ments  were  conducted.  In  the  first,  incubation
with N-acetyl-D-galactosamine,  N-acetyl-D-glucos-
amine,  or  amantadine  HCI  preceded  by  15  or  60
min the  exposure  to  PHA  in  the  presence  of  uri-
dine-2-i
4C.  Data from these experiments  (Fig.  1 A
and B) clearly  showed  that both N-acetyl-D-galac-
tosamine  and  amantadine  inhibited  RNA synthe-
sis  of  untreated  and  PHA-treated  lymphocytes.
However,  at  lower  concentrations  of  N-acetyl-D-
galactosamine  or  amantadine,  there  was  only  a
minimal  effect  on  control  cells,  but  a  30-40%
inhibition of the PHA-stimulated  cells. The stimu-
lation  of RNA  synthesis  due  to  PHA  was practi-
cally  abolished  at these  concentrations.  Thus,  the
initial  enhancement  of  RNA  synthesis  due  to
incubation  for  1 hr with  PHA  could  be  counter-
acted  by  preincubation  with  either  N-acetyl-D-
galactosamine  or  amantadine.  The  same  effect
could  be  shown  whether  the  cells  were  pre-
incubated for  15  or 60 min with either  N-acetyl-D-
galactosamine  or  amantadine.  N-acetyl-D-glucos-
amine, from 2 to  100 mg/ml, tested under the same
conditions  did  not  affect  the  incorporation  of
uridine-2-1
4 C into RNA.
In  the  second  series  of experiments,  PHA  was
added  15  or  60  min  before  exposure  to  either
N-acetyl-D-galactosamine  or  amantadine  in  the
presence  of  uridine-2-t4C.  N-acetyl-D-galactos-
amine or amantadine was added at concentrations
shown  previously  not  to depress  RNA synthesis  of
control  cells. Under these circumstances,  there was
no  decrease  in  the  enhanced  synthesis  of  RNA
(Fig.  1 C).  Therefore,  N-acetyl-D-galactosamine
and amantadine may counteract the effect of PHA
in a competitive  manner.
Permeability  of  treated  lymphocytes  to  RNA
precursors was investigated  by measurement  of the
amount  of  soluble  intracellular  4C  label  from
uridine-2-'4C.  For  this  purpose,  the  quantity  of
bound  and  PCA-soluble  tracer  was  determined.
The data,  summarized  in Table I,  showed  that in
PHA-treated  lymphocytes  both  the  soluble-  and
insoluble-labeled  compounds  were  present  at
higher  concentrations  than  in  the  corresponding
untreated  cells.  However,  when  N-acetyl-D-galac-
tosamine  and/or  amantadine  were  added,  the
concentrations  of  soluble  and  bound  tracer  were
lower  than  in  the  PHA-treated  cells.  Addition
of  N-acetyl-D-galactosamine  plus  amantadine  to
the same culture  did not have  a synergistic  inhibit-
ing effect.  This is also  suggestive of a common site
of action for both these inhibitors and PHA.
It  was  previously  found  (4,  5)  that shortly  after
additions  of PHA the incorporation  of amino acids
into  proteins  and  acetate  into  histones  is  stimu-
lated. For  determining whether  an altered  perme-
ability to metabolites was a more general effect elic-
ited by these  substances,  tests comparable  to those
TABLE  I
Incorporation  of Uridine-2-'
4C into  the RNA  and the PCA-Soluble Fraction of PHA-Treated and Control Cells
5  X  106  lymphocytes  per  ml were  preincubated  for  15  min with  6 mg/ml of N-acetyl-D-galactosa-
mine  or  10  /ug/ml of amantadine  or  with both compounds.  Following  the addition  of 0.5 mg/ml  of
PHA plus  1 gc/ml  of uridine-2-'4C  (sp.  act.  50 mc/mmole),  the  cells were  incubated  at 37°C for 1 hr.
mpmoles  uridine per pg RNA-P*  ppmoles uridine  PCA-soluble fraction
Conditions  PHA-treated  cells  Control  cells  PHA-treated  cells  Control cells
44.0  i  8.0  27.5  - 4.0  190.0 i  50.0  110.0  4- 30.0
N-acetyl-D-galactosamine  (6  25.0  4  7.0  25.5  7.0  85.0 4  30.0  90.0  i  30.0
mg  ml)
Amantadine  HCI  (10 ,g/ml)  27.5  i  6.0  25.5  - 6.0  87.0 i  30.0  75.0  i  30.0
N-acetyl-D-galactosamine  and  29.5  - 2.0  28.5  2.0  90.0  20.0  100.0  20.0
amantadine  HC1
* Mean  standard error of the mean.
$ Corrected  for the variable quantities of RNA in the  samples.
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Incorporation  of D-Alanine-'
4C into Protein and PCA-Soluble Fraction of PHA-Treated and
Control Cells
Experimental  conditions were  similar  to those given in  Table  I. D-alanine-UL-
14C,  1 pC  ml  (sp.  act.  112  mc/mmole),  was used  as a precursor.
psmoles D-alanine per  moles o-alanine  PCA-
mg protein*  soluble fraction
PHA-treated  Control  PHA-treated  Control
Conditions  cells  cells  cells  cells
16.5  7.0  73.0  37.0
N-acetyl-D-galactosamine  (6  mg/ml)  12.0  6.0  49.0  26.0
Amantadine  HCI  (10  mg/ml)  9.0  6.0  47.0  37.0
N-acetyl-D-galactosamine  and  amantadine  10.0  6.0  43.0  26.0
HCI
* Average  of two  different determinations.
$ Corrected  for the variable  quantities  of protein  in the samples.
TABLE  III
Incorporation of Acetate-2-
14C  into Proteins, Lipids, and PCA-Soluble Fraction of PHA-Treated and Control
Cells
Experimental conditions were similar  to those given in Table  I. Na acetate-2-
4 C, 5 pc/ml  (sp.  act.
22.5  mc/mmole),  was used  as a precursor.
AImoles acetate/mg  protein*
Protein fraction  Lipid fraction$  PCA-soluble  fractions
PHA-  PHA-  PHA-
treated  Control  treated  Control  treated  Control
Conditions  cells  cells  cells  cells  cells  cells
88.0  52.0  1,700.0  1,000.0  3,940.0  2,300.0
N-acetyl-D-galactosamine  44.0  52.0  1,300.0  1,470.0  2,350.0  2,300.0
Amantadine  HCI  47.0  52.0  870.0  930.0  1,500.0  2,130.0
N-acetyl-D-galactosamine  and  44.0  59.0  800.0  870.0  1,640.0  2,060.0
amantadine  HCI
* Average of two different  determinations.
$ Corrected  for the variable quantities of protein in the samples.
made with uridine were carried out with D-alanine
UL-
54C,  as  a  precursor  of proteins,  and  Na  ace-
tatel  =12-14C,  as  a  precursor  for  both lipids  and
proteins.  In  Tables  II  and III, containing  a sum-
mary  of  these  results,  it may  be  seen  that,  in  all
cases,  PHA  stimulated  the  incorporation  of ala-
nine  into the PCA-soluble  and insoluble fractions,
and of acetate into lipid, protein,  and PCA-soluble
fractions.  As  in  the  case  of uridine,  N-acetyl-D-
galactosamine  and  amantadine  depressed  incor-
poration.  Cell  transformation  and  DNA  synthesis
were  also inhibited  from 40  to 50%  after  72  hr of
culture  (not  reported  here).
From  these  experiments,  it  can  be  concluded
that agents  thought  to  act at the  cell  surface  are
capable  of inhibiting  the  PHA  stimulation  of the
synthesis  of RNA,  protein,  and  lipid,  perhaps  by
competing with PHA at  some common  site on  the
membrane.
The  rapid  binding  of  PHA  by  different  cell
membranes has been studied by Steck and Wallach
(15),  who  demonstrated  clearly  the  existence  of
574  B  R  SE F  N  0  T  E  Ssurface  receptors  common  to  many  cell  types.
Their  findings  exclude  the  possibility  that  pino-
cytosis is utilized  by the  cell  for  internalizing  the
PHA molecule.
Clumping  or  agglutination  of lymphocytes  was
not  altered  by  the  concentrations  of N-acetyl-D-
galactosamine  and  amantadine  used  to  inhibit
RNA,  protein,  or  lipid  synthesis  and  cell  trans-
formation.  Therefore,  the leukoagglutinating  prop-
erty of the PHA can  be dissociated  from its  mito-
genic  activity.  Thus,  permeability  changes  of the
membrane  itself  seem  to  be  the  primary  conse-
quence  of PHA  action  during the  early  stages,  as
postulated  by  Nowell.  However,  the  possibility
that  changes  in  membrane  permeability  stem
directly  from  an  intensified  cell  activity  (which
ultimately  is  manifested  in  mitosis)  cannot  be
ruled out.
Two  recent  reports,  one  dealing  with  the  oua-
bain  inhibition  of  lymphocyte  transformation  by
blocking the  Na+-  and  K
+ - dependent  adenosine
triphosphatase  activity  (16),  and  the  other  with
the  increase  in  permeability to  neutral red in  cells
exposured  to PHA for  1 hr (17),  are in good agree-
ment with the results reported here.
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Note Added in Proof
When  this  manuscript  was  in  preparation,  a
report on the effect of several  sugars on mitogenic and
binding  properties  of PHA  applied to  tonsil  cells  by
H.  Borberg,  . Yesner,  G.  Gesner,  and  R.  Silber
appeared  in  Blood.  1968.  31:747.
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